CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γ(c) cytokine stimulation via PI3K/mTOR axis

Obinutuzumab is a glycoengineered tumor-targeting anti-CD20 mAb with a modified crystallizable fragment (Fc) domain designed to increase the affinity for the FcγRIIIA/CD16 receptor, which was recently approved for clinical use in CLL and follicular lymphoma. Here we extend our previous observation t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Immunol Immunother
Auteurs principaux: Capuano, Cristina, Pighi, Chiara, Maggio, Roberta, Battella, Simone, Morrone, Stefania, Palmieri, Gabriella, Santoni, Angela, Klein, Christian, Galandrini, Ricciarda
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7113231/
https://ncbi.nlm.nih.gov/pubmed/31950225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02482-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires